In: Oncogene, 2019, vol. 38, no. 15, p. 2814–2829
Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER−) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual cancer cells, however, there is no formal evidence for it. Here, we provide experimental...
|
In: Acta Neuropathologica, 2013, vol. 126, no. 1, p. 159-159
|
In: Acta Neuropathologica, 2012, vol. 124, no. 4, p. 547-560
|
In: Human Molecular Genetics, 2007, vol. 16, no. 15, p. 1845-1861
|
In: Human Molecular Genetics, 2006, vol. 15, no. 6, p. 965-977
|
In: Journal Of The National Cancer Institute, 2014, vol. 106, no. 10, p. -
|
In: Journal Of The National Cancer Institute, 2015, vol. 107, no. 5, p. -
|
In: Bioinformatics, 2011, vol. 27, no. 12, p. 1729-1730
|
In: Journal of the National Cancer Institute, 2011, vol. 103, no. 11, p. 841-844
|
In: Journal of the National Cancer Institute, 2006, vol. 98, no. 17, p. 1183-1192
|